Live tape
Top 8, mentions 7d10,061TSLA2,067 mentions▲ +0.05GOOGL1,606 mentions▲ +0.04NVDA1,230 mentions▲ +0.07CRWV1,216 mentions▲ +0.03SPCX1,103 mentions▲ +0.07QQQ1,074 mentions▲ +0.04META891 mentions▲ +0.05NBIS874 mentions▲ +0.06

Equity · Healthcare

ALKS

NASDAQ

Alkermes plc

$41.20 +2.77% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 16, 2026
Price · Chart
63 sessions
$55 $35 21 Jul 16 Oct

The line runs $53 on 21 July through $41.20 on 16 October, on a scale from $35 to $55. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 63 sessions, 21 Jul – 16 Oct 2026
Market cap $6.9B
P/E (TTM) 108.4
52-week range $27.21 – $55
Avg volume 144.1K

as of Oct 16, 2026

ALKS insider trades

SEC Form 4 · last 90 days · newest reported trade 2 Oct 2026
Open-market buys 0
Open-market sells 7
Net sold $3.75M
Non-trade filings 5
Date Insider Type Shares Value
02 Oct 2026 Gaffin David Joseph EVP, CLO, Alkermes, Inc. Sell 2,034 $83K
03 Sep 2026 Gaffin David Joseph EVP, CLO, Alkermes, Inc. Sell 2,034 $98K
01 Sep 2026 Hopkinson Craig C. EVP R&D, Chief Medical Officer Sell 9,000 $423K
17 Aug 2026 Nichols Christian Todd SVP, Chief Commercial Officer Sell 7,576 $373K
03 Aug 2026 Gaffin David Joseph EVP, CLO, Alkermes, Inc. Sell 2,034 $99K
03 Aug 2026 Hopkinson Craig C. EVP R&D, Chief Medical Officer Sell 9,000 $437K
03 Aug 2026 snyderman nancy lynn MD Director Sell 44,472 $2.24M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Oct 2026 Reed Joshua SVP, Chief Financial Officer Option exercise 9,164
08 Oct 2026 Reed Joshua SVP, Chief Financial Officer Tax withheld 4,069 $163K
01 Sep 2026 Hopkinson Craig C. EVP R&D, Chief Medical Officer Option exercise 5,000 $123K
03 Aug 2026 Hopkinson Craig C. EVP R&D, Chief Medical Officer Option exercise 5,000 $122K
03 Aug 2026 snyderman nancy lynn MD Director Option exercise 44,472 $2.08M

ALKS reported financials

SEC EDGAR XBRL SEC EDGAR

ALKS reported revenue of $1.5B for the fiscal year ended 31 Dec 2025. Net income over the same period was $241.7M.

Figure Reported Period
Revenue $1.5B 31 Dec 2025 fiscal year
Net income $241.7M 31 Dec 2025 fiscal year
Diluted EPS $1.43 31 Dec 2025 fiscal year
Total assets $4.4B 30 Jun 2026 at period end
Total equity $1.8B 30 Jun 2026 at period end

ALKS earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.00 $496M
31 Mar 2026 Q1 2026 −$0.40 $393M
31 Dec 2025 FY 2025 $1.43 $1.48B
30 Sep 2025 Q3 2025 $0.49 $394M
30 Jun 2025 Q2 2025 $0.52 $391M
31 Mar 2025 Q1 2025 $0.13 $307M
31 Dec 2024 FY 2024 $2.17 $1.56B
30 Sep 2024 Q3 2024 $0.55 $378M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ALKS institutional holders

SEC Form 13F SEC EDGAR

12 of the 45 institutional funds we track reported a ALKS position for the quarter ended 30 Jun 2026 — a combined $1.2B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 10,012,267 $524.6M
Renaissance Technologies Held (±25%) +4.9% shares 6,460,928 $338.5M
Citadel Advisors Trimmed −26.6% shares 1,645,101 $86.2M
D. E. Shaw & Co. Added +84.7% shares 1,312,031 $68.7M
Two Sigma Investments Added +33.0% shares 1,038,311 $54.4M
Marshall Wace Held (±25%) −2.9% shares 969,954 $50.8M
Fisher Asset Management Held (±25%) +7.3% shares 419,102 $22.0M
Millennium Management New position 319,595 $16.7M
AQR Capital Management Trimmed −44.5% shares 212,968 $11.2M
Balyasny Asset Management Trimmed −75.7% shares 142,366 $7.5M

Showing the 10 largest of 12 reported positions. The figures above count all of them.

ALKS fails-to-deliver

SEC CNS data SEC

On 23 Sep 2026, 722 shares of ALKS failed to deliver (about $31K).

Settlement date Shares failed Notional % of shares out
23 Sep 2026 722 $31K <0.001%

Congressional trades in ALKS

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in ALKS is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 29 Sep 2026.

Date Member Type Amount
29 Sep 2026 filed 12 Oct 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K
30 Jul 2026 filed 04 Sep 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $15K–$50K

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings
  8. Wikipediatext of the lead paragraph, licensed CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) — https://en.wikipedia.org/wiki/Alkermes_plc